Aclarion News

Maxim Group Downgrades Aclarion(ACON.US) to Hold Rating

Moomoo NewsDec 13, 2024 09:31 ET

Ascendiant Maintains Aclarion(ACON.US) With Buy Rating, Cuts Target Price to $1.3

Moomoo NewsNov 28, 2024 11:31 ET

Aclarion Analyst Ratings

BenzingaNov 27, 2024 05:33 ET

Aclarion Analyst Ratings

BenzingaAug 26, 2024 05:50 ET

Maxim Group Maintains Aclarion(ACON.US) With Buy Rating

Moomoo NewsAug 23, 2024 08:33 ET

Maxim Group Maintains Aclarion(ACON.US) With Buy Rating

Moomoo NewsAug 22, 2024 16:32 ET

Maxim Group Remains a Buy on Aclarion, Inc. (ACON)

TipRanksAug 22, 2024 16:00 ET

Aclarion Analyst Ratings

BenzingaJul 29, 2024 06:31 ET

Ascendiant Initiates Aclarion(ACON.US) With Buy Rating, Announces Target Price $1.6

Moomoo NewsJul 29, 2024 05:32 ET

Analysts Are Bullish on Top Healthcare Stocks: Calliditas Therapeutics (CALT), Aclarion, Inc. (ACON)

TipRanksMay 23, 2024 13:45 ET

Aclarion, Inc. (ACON) Receives a Buy From Maxim Group

TipRanksMar 2, 2023 07:41 ET

Maxim Group Sticks to Its Buy Rating for Aclarion, Inc. (ACON)

TipRanksAug 23, 2022 12:05 ET

Aclarion Price Target Announced at $3.00/Share by Maxim Group

Dow JonesJul 6, 2022 08:28 ET

Aclarion Initiated at Buy by Maxim Group

Dow JonesJul 6, 2022 08:28 ET

Maxim Group Initiates Coverage On Aclarion with Buy Rating, Announces Price Target of $3

Benzinga Real-time NewsJul 6, 2022 08:20 ET

Aclarion analyst ratings

Benzinga Analyst RatingsJul 6, 2022 08:18 ET

Maxim Starts Aclarion at Buy With $3 Price Target

MT NewswiresJul 6, 2022 08:04 ET